NeuroBo Pharmaceuticals, Inc.

NRBO

US64132R4048

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 29/06/2024 am IST			5-day change	1st Jan Change
4.84 ^USD	+0.83%		+19.21%	+30.93%

26/06	NeuroBo Pharmaceuticals, Inc. Doses First Patient in the MAD Part 2 of its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity	CI
26/06	NeuroBo Pharmaceuticals Raises $20 Million from Share Placement	MT

NeuroBo Pharmaceuticals, Inc. announced that it has received $17.000005 million in funding from Dong-A ST Co., Ltd.

June 25, 2024

On June 25, 2024, NeuroBo Pharmaceuticals, Inc., closed the transaction.

Stocks mentioned in the article

	Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
	DONG-A ST CO., LTD.	62,900 KRW	0.00%	-0.94%	40Cr
	NEUROBO PHARMACEUTICALS, INC.	4.84 USD	+0.83%	+19.21%	4.84Cr

Latest news about NeuroBo Pharmaceuticals, Inc.

NeuroBo Pharmaceuticals, Inc. Doses First Patient in the MAD Part 2 of its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity	26/06	CI
NeuroBo Pharmaceuticals Raises $20 Million from Share Placement	26/06	MT
NeuroBo Pharmaceuticals, Inc. announced that it has received $17.000005 million in funding from Dong-A ST Co., Ltd.	25/06	CI
NeuroBo Pharmaceuticals Announces Private Placement, Registered Direct Offering	24/06	MT
NeuroBo Pharmaceuticals, Inc. Announces Pre-Clinical Data	22/06	CI
NeuroBo Pharmaceuticals, Inc. Announces Pre-Clinical Data of DA-1241, a Novel G-Protein-Coupled Receptor 119 Agonist, in Combination with Semaglutide	22/05	CI
NeuroBo Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05	CI
Maxim Initiates NeuroBo Pharmaceuticals With Buy Rating, $10 Price Target	08/05	MT
Sector Update: Health Care Stocks Mixed Wednesday Afternoon	17/04	MT
NeuroBo Begins Dosing in Phase 1 Study of Obesity Treatment; Shares Rise	17/04	MT
NeuroBo Pharmaceuticals, Inc. Doses First Patient in Its Phase 1 Clinical Trial Evaluating Da-1726 for the Treatment of Obesity	17/04	CI
NeuroBo Pharmaceuticals, Inc. Completes Enrollment of Part 1 of Its Phase 2A Clinical Trial Evaluating DA-1241 for the Treatment of Mash	01/04	CI
NeuroBo Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/03	CI
NeuroBo Pharmaceuticals to Continue Trial of Liver Disease Treatment Candidate -- Shares Down	13/03	MT
NeuroBo Pharmaceuticals, Inc. Receives Safety Review Committee Approval to Continue with Its Phase 2A Clinical Trial Evaluating DA-1241 for the Treatment of Mash	13/03	CI
NeuroBo Pharmaceuticals Names Marshall Woodworth Finance Chief	04/03	MT
NeuroBo Pharmaceuticals, Inc. Announces the Appointment of Marshall Woodworth as Chief Financial Officer	04/03	CI
NeuroBo Pharmaceuticals, Inc. Receives First Site IRB Approval for Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity	29/02	CI
US Equity Markets Close Higher Thursday Following Jobless Claims Data	02/02	MT
Sector Update: Health Care Stocks Rise in Late Afternoon	02/02	MT
Sector Update: Health Care Stocks Rise in Thursday Afternoon Trading	02/02	MT
Top Midday Gainers	02/02	MT
NeuroBo Gets FDA Clearance For DA-1726 Trial in Obesity; Shares Soar	01/02	MT
NeuroBo Shares Surge as Obesity Drug Moves to Phase I Trial	01/02	DJ
NeuroBo Pharmaceuticals Announces FDA Clearance of IND for a Phase 1 Clinical Trial of DA-1726 for the Treatment	01/02	CI

Chart NeuroBo Pharmaceuticals, Inc.

Duration

Period

More charts

NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. It is developing DA-1241 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Type 2 Diabetes Mellitus (T2DM), and is developing DA-1726 for the treatment of obesity. DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and T2DM. Agonism of GPR119 in the gut promotes the release of key gut peptides, glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide, and peptide YY. DA-1726 is a novel oxyntomodulin (OXM) analogue functioning as a GLP-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist for the treatment of obesity that is to be administered once weekly subcutaneously. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure.

Sector

Biotechnology & Medical Research

Calendar

13/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

4.84 USD

Average target price

27.67 USD

Spread / Average Target

+471.63%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
NEUROBO PHARMACEUTICALS, INC.	+30.93%	4.84Cr
VERTEX PHARMACEUTICALS INCORPORATED	+15.20%	12TCr
REGENERON PHARMACEUTICALS, INC.	+19.67%	11TCr
ARGENX SE	+18.95%	2.6TCr
BIONTECH SE	-23.86%	1.94TCr
GENMAB A/S	-19.03%	1.59TCr
BEIGENE, LTD.	-20.90%	1.51TCr
WUXI APPTEC CO., LTD.	-46.14%	1.51TCr
SAREPTA THERAPEUTICS, INC.	+63.85%	1.49TCr
NEUROCRINE BIOSCIENCES, INC.	+4.49%	1.39TCr

Bio Therapeutic Drugs